CPHYX Performance — High Yield Fund, Class A
Data updated: 2026-09-25
CPHYX returned +1.30% year to date and +3.83% over one year to Jul 2026. Annualised returns are +6.96% over 3 years and +3.74% over 5 years. The fund trailed its High Yield Bond category average: $100 invested three years ago grew to $122, against $123 for the category, and to $104 over one year, against $105. Volatility over the past three years was 4.12% a year. In the 12 months to Jul 2026 the fund lost a net $2.5B, and assets reached $3.84B.
CPHYX Growth of $100
What $100 invested in High Yield Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the High Yield Bond category average over the same months.
| Period | CPHYX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $104 | $105 |
| 3 years (Aug 2023 – Jul 2026) | $122 | $123 |
| 5 years (Aug 2021 – Jul 2026) | $120 | $118 |
| Since data start (Aug 2019 – Jul 2026) | $136 | $132 |
CPHYX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +1.30% |
| 1 year | +3.83% |
| 3 years (annualised) | +6.96% |
| 5 years (annualised) | +3.74% |
CPHYX Annual Returns
Calendar-year total returns of High Yield Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +1.30% |
| 2025 | +6.68% |
| 2024 | +7.05% |
| 2023 | +12.38% |
| 2022 | −8.53% |
| 2021 | +5.39% |
| 2020 | +6.09% |
| 2019 (Aug–Dec) | +2.54% |
CPHYX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.5% | +0.2% | −1.2% | +1.6% | +0.4% | +0.2% | −0.4% | — | — | — | — | — |
| 2025 | +1.5% | +0.5% | −1.4% | −0.1% | +1.6% | +1.7% | +0.2% | +1.0% | +0.5% | 0.0% | +0.2% | +0.7% |
| 2024 | +0.2% | +0.2% | +1.1% | −0.7% | +1.0% | +0.9% | +1.6% | +1.5% | +1.2% | −0.5% | +1.0% | −0.6% |
| 2023 | +3.4% | −1.4% | +1.6% | +0.9% | −1.0% | +1.4% | +1.2% | +0.3% | −1.3% | −1.0% | +4.2% | +3.6% |
| 2022 | −2.1% | −0.6% | −0.7% | −2.9% | −0.3% | −6.1% | +5.4% | −2.0% | −4.0% | +2.9% | +2.7% | −0.6% |
| 2021 | +0.2% | +0.5% | +0.4% | +1.1% | +0.4% | +1.3% | +0.3% | +0.4% | +0.1% | −0.3% | −0.9% | +1.7% |
| 2020 | −0.3% | −1.6% | −10.4% | +4.0% | +4.2% | +0.4% | +4.8% | +0.9% | −0.9% | +0.9% | +3.2% | +1.6% |
| 2019 | — | — | — | — | — | — | — | +0.3% | 0.0% | 0.0% | +0.4% | +1.8% |
CPHYX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 4.12%
- 3-year Sharpe ratio: 0.60 (vs 4.5% risk-free rate)
- Best month: +4.17% (Nov 2023)
- Worst month: −1.39% (Mar 2025)
CPHYX Fund Flows
Monthly money in and out of High Yield Fund, from SEC Form N-PORT.
- 12-month net flow: −$2.5B
- 12-month gross sales (incl. reinvestments): $1.6B
- Sales ÷ redemptions: 0.39×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $104.7M | $104.6M | $159K |
| Jun 2026 | $80.6M | $78.9M | $1.7M |
| May 2026 | $89.8M | $2.6B | −$2.5B |
| Apr 2026 | $243.7M | $141.9M | $101.8M |
| Mar 2026 | $96.7M | $278.4M | −$181.7M |
| Feb 2026 | $161.3M | $89.8M | $71.5M |
| Jan 2026 | $85.0M | $188.1M | −$103.2M |
| Dec 2025 | $90.5M | $99.5M | −$9.1M |
| Nov 2025 | $84.8M | $76.0M | $8.8M |
| Oct 2025 | $288.6M | $170.4M | $118.2M |
| Sep 2025 | $167.8M | $149.2M | $18.6M |
| Aug 2025 | $85.1M | $86.5M | −$1.4M |
CPHYX Assets Under Management
Net assets of High Yield Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $3.84B |
| 2026-04-30 | $6.43B |
| 2026-01-31 | $6.51B |
| 2025-10-31 | $6.62B |
| 2025-07-31 | $6.50B |
| 2025-04-30 | $6.06B |
| 2025-01-31 | $5.98B |
| 2024-10-31 | $5.83B |
| 2024-07-31 | $2.53B |
| 2024-04-30 | $2.50B |
| 2024-01-31 | $2.51B |
| 2023-10-31 | $2.30B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.